Introduction
============

Age-related macular degeneration (AMD) is a major cause of visual impairment and blindness among older people \[[@r1]\]. The alternative pathway of the complement system, an ancient defense against infectious microbes \[[@r2],[@r3]\], is implicated in the etiology and pathogenesis of the disease. Local and systemic complement activation occurs in individuals with AMD \[[@r4],[@r5]\]. The proteins of the complement system and products of their activation are found to be raised in the circulation and in local deposits (drusen) in the retina \[[@r4]\]. Genome-wide association studies first revealed the association between polymorphisms in the complement factor H (*CFH*) gene and susceptibility to the disease \[[@r6]-[@r8]\]. Since then, risk-associated polymorphisms in complement factor I (*CFI*) \[[@r9]\], complement factor B (*CFB*) \[[@r10]\], complement component 3 (*C3*) \[[@r11]\], complement factor H-related 3 (*CFHR3*), and complement factor H-related 1 (*CFHR1*) \[[@r12]\] genes have been discovered and replicated. Progress has been made toward understanding the functional effects of the I62V and Y402H \[[@r13]-[@r15]\] polymorphisms in *CFH*, the deletion of *CFHR3* and *CFHR1* \[[@r16]\], and the R32Q polymorphism in *CFB* \[[@r17]\].

The central step of all three complement pathways is activation of the C3 molecule to C3b by a C3 convertase enzyme \[[@r3]\]. In the alternative pathway, the C3 convertase is made by the binding of C3b to CFB, forming the proenyzme C3bB. An enzyme, complement factor D (CFD), cleaves the CFB part of the proenzyme, separating the Ba fragment of the molecule from the active C3bBb complex. Montes et al. \[[@r17]\] studied the effect of two adjacent genetic polymorphisms on the function of human and recombinant CFB in vitro. These single nucleotide polymorphisms, [rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153) (R32Q) and [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614) (R32W), affect the same codon and amino acid residue. Of the four possible combinations of bases, three are found to exist, with the combination of both major alleles resulting in an arginine (R), the minor allele of [rs641153](http://www.ncbi.nlm.nih.gov/snp?term=rs641153) with the major allele of [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614) resulting in a glutamine (Q), and the minor allele of [rs12614](http://www.ncbi.nlm.nih.gov/snp?term=rs12614) with the major allele of [rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153) resulting in a tryptophan (W) at residue 32 ([Table 1](#t1){ref-type="table"}). This residue is in the Ba fragment of CFB, and is part of the binding site for C3b \[[@r17]\]. Compared to 32R, the 32Q variant of CFB binds with fourfold reduced affinity to C3b, reducing formation of the C3bB proenzyme and reducing lytic activity \[[@r17]\]. The 32W variant of CFB also exhibits reduced binding, proenzyme formation and lytic activity relative to 32R, but the reduction is less marked than that found with 32Q \[[@r17]\]. The 32Q variant is associated with a reduced risk of developing AMD \[[@r10]\]. The 32W variant has been studied by several groups \[[@r5],[@r10],[@r18],[@r19]\], but has not been found to be associated with AMD risk. In this study, we investigate the risk of AMD associated with the 32R, 32W, and 32Q variants of CFB. Statistical analysis is presented for these variants alone, and in a logistic regression incorporating the other major genetic risk factors, *CFH* and *HTRA1*, and smoking status. We also perform a meta-analysis of data from all identified studies that have previously investigated [rs12614](http://www.ncbi.nlm.nih.gov/snp?term=rs12614) (R32W) in AMD.

###### Complement factor B (CFB) codon 32 sequences and amino acids

  **Codon 32 sequence**   **Amino acid**   **Symbol**
  ----------------------- ---------------- ------------
  CGG                     Arginine         R
  TGG                     Tryptophan       W
  CAG                     Glutamine        Q

Three sequence variants are found in codon 32 due to variations at the first base ([rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614): C/T) and second base ([rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153): A/G) of the codon. Three different amino acids are therefore found at residue 32 of the CFB protein. The genotype at both SNPs must be known to predict the presence of the 32R protein variant.

Methods
=======

Study participants
------------------

The characteristics of the study group are shown in [Table 2](#t2){ref-type="table"}. Individuals with neovascular AMD in at least one eye were recruited between June 2002 and September 2006 from ophthalmology clinics in the Royal Victoria Hospital, Belfast, UK, the regional referral center for Northern Ireland. Diagnosis was made by clinical examination and fluorescein angiography. Stereoscopic digital fundus photographs were graded according to the Wisconsin age-related maculopathy grading system \[[@r20]\]. Cases had grade 4 neovascular AMD with or without geographic atrophy. Control participants were recruited from the local population, and they underwent retinal photography. Those included had grade 1a retinas (free of drusen or fewer than five hard drusen with a diameter of \<63 µm). All participants self-reported European ancestry.

###### Study characteristics.

  **Characteristics**         **Grade 4 AMD cases**   **Grade 1a controls**
  --------------------------- ----------------------- -----------------------
  Participants (n)            369                     251
  Male                        42%                     48%
  Female                      58%                     52%
  Median age (range; years)   76 (54--93)             75 (68--92)

Age refers to the age at recruitment into the study.

The study conformed to the tenets of the declaration of Helsinki, and it was approved by the Office for Research Ethics Committees, Northern Ireland. All participants gave informed consent.

Genotyping of [rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153) and [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614)
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

DNA was extracted from peripheral blood leucocytes or frozen buffy coat samples. We performed SNP genotyping of [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614) and [rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153) by PCR (forward primer: 5′-ACA CAC CAT CCT GCC CCA G-3′; reverse primer: 5′-TAC CCC CTC CAG AGA GCA GG-3′) followed by DNA sequencing using the forward primer. All samples showing the minor allele of [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614) were confirmed using SNaPshot (Applied Biosystems, Warrington, UK). Briefly, primer (5′-CAG GTG TGA CCA CCA CTC CAT GGT CTT TGG CC-3′) extension was performed on the PCR product using a fluorescent detection system. Data for the smoking status and *CFH* and *HTRA1* haplotypes of these participants were available from our previous studies \[[@r12],[@r21]\].

Statistical analysis
--------------------

Deviation from the Hardy--Weinberg equilibrium was investigated by use of the exact method of Wigginton et al. \[[@r22]\] as used in [PLINK v1.07](http://pngu.mgh.harvard.edu/~purcell/plink/) \[[@r23]\]. Logistic regression was performed using [PASW v18](http://www.spss.com/software/statistics/products/). The numbers of copies (0, 1, or 2) of each *CFH* haplotype and *CFB* codon 32 variant carried by an individual were included as variables, omitting a reference haplotype from each gene. *CFH* haplotypes were tagged by [rs6677604](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=6677604), [rs3753396](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3753396), [rs419137](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=419137), and [rs2284664](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2284664) (1: GACG; 2: GAAG; 3: GGAG; 4: GAAA; 5: AAAG), with haplotype 3 omitted as the reference. The heterozygous or homozygous state for the *HTRA1* risk allele ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924); T) was included, with homozygosity for the major allele ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924); G) omitted as the reference. Current smoking and past smoking were included in the model as binary variables, with having never smoked omitted as the reference. Associations between disease status and allele frequency in the studies performed by ourselves and other groups were investigated using Pearson's χ^2^ test in [Epi-Info v6](http://wwwn.cdc.gov/epiinfo/). To enable comparison of data sets from other groups, we used their published data, multiplying allele frequencies by the number of cases or controls to give the allele count if these were not published. For the meta-analysis, we compared the counts of 32W and 32Q alleles to the reference variant, 32R. Statistical significance was accepted at p\<0.05 for all tests.

Results
=======

Both [rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153) and [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614) were in Hardy--Weinberg equilibrium in cases and controls. The genotyping rate was 99.7%. *CFB* genotype data were available for 618 participants.

Logistic regression of complement factor B 32R, 32W, and 32Q
------------------------------------------------------------

The 32Q and 32W variants of CFB were found to be protective against the disease when compared to the 32R variant ([Table 3](#t3){ref-type="table"}). The 32Q variant was associated with an odds ratio of 0.43 (p=8.1×10^−5^), and the 32W variant was associated with an odds ratio of 0.64 (p=0.04).

###### Logistic regression of complement factor B (CFB) variants.

  **Variant**   **Odds ratio**   **95% Confidence interval**   **p value**   
  ------------- ---------------- ----------------------------- ------------- ------------
  32R           1 (reference)                                                 
  32W           0.64             0.42                          0.98          0.04
  32Q           0.43             0.28                          0.65          8.1×10^−5^
  Constant      1.81                                                         2.0×10^−9^

A logistic regression of the three amino acid variants at residue 32 of the CFB protein. The genotypes were coded as 0, 1 or 2 copies of each variant.

###### Logistic regression of complement factor B (CFB) codon 32 type, complement factor H (*CFH*) haplotypes, *HTRA1* [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) genotype and smoking status.

  **Covariates**                   **Odds ratio**   **95% Confidence interval**   **P value**   
  -------------------------------- ---------------- ----------------------------- ------------- -------------
  *CFH* haplotype 1                1.91             1.20                          3.04          6.7×10^−3^
  *CFH* haplotype 2                2.41             1.64                          3.52          6.5×10^−6^
  *CFH* haplotype 4                1.12             0.71                          1.75          0.63
  *CFH* haplotype 5                0.47             0.28                          0.78          4.0×10^−3^
  CFB 32W                          0.53             0.31                          0.91          0.02
  CFB 32Q                          0.33             0.19                          0.56          5.1×10^−5^
  *HTRA1* risk heterozygote (AT)   3.40             2.20                          5.26          3.9×10^−8^
  *HTRA1* risk homozygote (TT)     25.04            11.24                         55.78         3.3×10^−15^
  Ex-smoker                        1.73             1.10                          2.71          0.02
  Current smoker                   3.61             2.00                          6.49          1.9×10^−5^
  Regression constant              0.29                                                         5.9×10^−5^

A logistic regression of genetic variants and smoking status. *CFB* and *CFH* data were coded as 0, 1 or 2 copies of each allele. Complete data were available for 351 cases and 222 controls to allow inclusion in the logistic regression model. *CFH* haplotypes are defined in Methods.

###### Review and meta-analysis of all identified previous reports of rs12614 (R32W) polymorphism in AMD

  **Study**       **Case phenol** **type**   **Population**      **Study size**   **Cases**   **Controls**   **32W**   **32Q**                                                               
  --------------- -------------------------- ------------------- ---------------- ----------- -------------- --------- --------- ----- ------ ------ ------------ ------ ------ ------------ --------------
  Current study   NV                         European            618              52          39             643       49        58    395    0.65   0.42--1.00   0.04   0.41   0.26--0.64   2.9x10^−05^
  \[[@r10]\]      NV                         European-American   548              52          21             473       55        61    434    0.87   0.57--1.32   0.49   0.32   0.18--0.54   4.2 x10^−06^
  \[[@r18]\]      NV                         Caucasian           629              70          37             731       41        48    330    0.77   0.50--1.18   0.21   0.35   0.22--0.56   1.7 x10^−06^
  \[[@r10]\]      GA                         European-American   366              20          4              158       55        61    434    1.00   0.56--1.77   1.00   0.18   0.05--0.53   2.7 x10^−04^
  \[[@r10]\]      Early                      European-American   459              37          19             312       55        61    434    0.94   0.59--1.49   0.77   0.43   0.24--0.76   1.7 x10^−03^
  \[[@r10]\]      NV, GA, Early              European-American   823              109         44             943       55        61    434    0.91   0.64--1.31   0.60   0.33   0.22--0.51   2.6 x10^−08^
  \[[@r19]\]      NV, GA                     Indian              351              52          27             274       55        90    204    0.70   0.45--1.09   0.10   0.22   0.14--0.36   3.1 x10^−11^
  \[[@r5]\]       NV, GA, Drusen             Caucasian           179              25          6              193       7         10    117    2.17   0.86--5.69   0.08   0.36   0.11--1.12   0.05
  Meta-analysis   NV                                             1795             174         97             1847      145       167   1159   0.75   0.59--0.96   0.02   0.36   0.28--0.47   4.6 x10^−15^
  Meta-analysis   All                                            2600             308         153            2784      207       267   1480   0.79   0.65--0.96   0.01   0.30   0.25--0.38   1.8 x10^−31^

p values calculated using Pearson's χ^2^ test and allelic model. The odds ratios and p values for 32W and 32Q are calculated with reference to 32R. Phenotype and population descriptions are as reported in the original papers. NV=Neovascular AMD; GA=Geographic Atrophy; OR=Odds Ratio; CI=Confidence Interval; p=p value. The numbers from the Spencer et al. \[[@r18]\] and Kaur et al. \[[@r19]\] papers are derived from reported percentages and frequencies, therefore may be slightly inaccurate.

Logistic regression incorporating smoking status and genotypes in complement factor B, complement factor H, and *HTRA1*
-----------------------------------------------------------------------------------------------------------------------

The 32Q and 32W variants of CFB were found to be protective against AMD when smoking status and other known genetic risk loci were integrated into a logistic regression ([Table 4](#t4){ref-type="table"}). The gradation of effect was the same as in the individual regression, with 32Q being more protective than 32W (odds ratios 0.33 and 0.53, respectively). *CFH* haplotypes 1 and 2, which carry the Y402H risk allele \[[@r12]\], were associated with increased risk relative to haplotype 3 (odds ratios 1.91 and 2.41, respectively). *CFH* haplotype 5, which carries the deletion of *CFHR3* and *CFHR1* \[[@r12]\], was protective against AMD (odds ratio 0.47). The *HTRA1* risk allele was associated with increased risk, particularly in homozygosity (odds ratio 25.04). Past and current smoking were associated with increased risk (odds ratios 1.73 and 3.61, respectively) compared to having never smoked.

Meta-analysis of published studies of complement factor B 32R, 32W, and 32Q
---------------------------------------------------------------------------

The 32Q variant of CFB was significantly associated with protection from AMD in all of the studies that also reported data for 32W ([Table 5](#t5){ref-type="table"}). The 32W variant was associated with moderate protection from neovascular AMD in the current study and the Gold \[[@r10]\] and Spencer \[[@r18]\] studies, though the finding was not statistically significant in the latter two studies. Meta-analysis of these three neovascular AMD studies showed an odds ratio of 0.75 (p=0.02) for the 32W variant, compared to the 32R variant. Gold et al. \[[@r10]\] reported data for other AMD phenotypes, while Kaur \[[@r19]\] and Scholl \[[@r5]\] reported studies of mixed phenotypes. The trend in these studies was less consistent, with Gold reporting no association for geographic atrophy (though with wide confidence intervals) \[[@r10]\] and Scholl reporting a nonsignificant increase in risk (in a small study of mixed phenotype, with wide confidence intervals) \[[@r5]\]. Meta-analysis of all the studies that included all phenotypes showed that the 32W variant of CFB was associated with a significant reduction in risk of AMD (odds ratio 0.79, p=0.01).

Discussion
==========

Significant association between the minor allele at [rs12614](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12614) in *CFB* (32W) and decreased risk of neovascular AMD has not been reported previously. The study by Montes et al. \[[@r17]\] provided evidence that this polymorphism was associated with less efficient alternative complement pathway activation due to weakened binding between CFB and C3b. Their study also showed that the established protective 32Q variant (associated with the minor allele at [rs641153](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=641153)) was associated with a more extreme reduction in complement activation relative to 32R. We investigated the hypothesis that the genetic variant causing 32W was associated with protection from AMD, and found this to be the case when compared to 32R by Pearson's χ^2^, by logistic regression with [rs641153](http://www.ncbi.nlm.nih.gov/snp?term=rs641153) and by logistic regression that included other known risk factors for AMD. The two other studies of neovascular AMD (Gold \[[@r10]\] and Spencer \[[@r18]\]) showed nonsignificant protective effects (odds ratios 0.87 and 0.77, respectively). When all neovascular cases were examined in a meta-analysis, a statistically significant, moderately protective odds ratio (0.75; p=0.02) was revealed. A more significant, less strong odds ratio (0.79; p=0.01) was revealed when meta-analysis of all AMD cases was undertaken.

This association has not been detected previously. This discord may reflect chance findings of either our study or the studies of others. However, combined analysis of all available data supports the conclusion that CFB 32W is associated with moderate protection against neovascular AMD, a finding that is in keeping with the study by Montes et al., which showed decreased complement activation relative to CFB 32R \[[@r17]\].

Our study provides further evidence that an individual's risk of AMD is affected by gene polymorphisms that affect the function and interaction of the alternative complement pathway proteins.
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